Compare NXST & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXST | PTCT |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.7B |
| IPO Year | 2002 | 2006 |
| Metric | NXST | PTCT |
|---|---|---|
| Price | $187.57 | $67.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $263.75 | $80.65 |
| AVG Volume (30 Days) | 278.7K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 5.09 | N/A |
| Revenue | ★ $4,949,000,000.00 | $264,734,000.00 |
| Revenue This Year | $11.38 | N/A |
| Revenue Next Year | N/A | $17.70 |
| P/E Ratio | $37.19 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $164.00 | $43.18 |
| 52 Week High | $254.30 | $87.50 |
| Indicator | NXST | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 44.34 |
| Support Level | $182.45 | $62.87 |
| Resistance Level | $210.51 | $69.23 |
| Average True Range (ATR) | 8.22 | 2.83 |
| MACD | -0.80 | -0.34 |
| Stochastic Oscillator | 13.44 | 21.31 |
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Pending approval, Nexstar's merger with Tegna would bring Nexstar's station total to 259 in 133 markets, reaching 80% of the US population. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.